178 related articles for article (PubMed ID: 25081647)
41. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
42. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
43. MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy.
Zhong X; Xie G; Zhang Z; Wang Z; Wang Y; Wang Y; Qiu Y; Li L; Bu H; Li J; Zheng H
Oncotarget; 2016 Sep; 7(38):61166-61182. PubMed ID: 27533459
[TBL] [Abstract][Full Text] [Related]
44. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
Med Oncol; 2009 Dec; 26(4):480-90. PubMed ID: 19130322
[TBL] [Abstract][Full Text] [Related]
45. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
[TBL] [Abstract][Full Text] [Related]
46. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
47. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy.
Larsen MS; Bjerre K; Giobbie-Hurder A; Lænkholm AV; Henriksen KL; Ejlertsen B; Lykkesfeldt AE; Rasmussen BB
Acta Oncol; 2012 Jul; 51(6):781-9. PubMed ID: 22462654
[TBL] [Abstract][Full Text] [Related]
49. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.
Johnston SR; Saccani-Jotti G; Smith IE; Salter J; Newby J; Coppen M; Ebbs SR; Dowsett M
Cancer Res; 1995 Aug; 55(15):3331-8. PubMed ID: 7614468
[TBL] [Abstract][Full Text] [Related]
50. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
Bardou VJ; Arpino G; Elledge RM; Osborne CK; Clark GM
J Clin Oncol; 2003 May; 21(10):1973-9. PubMed ID: 12743151
[TBL] [Abstract][Full Text] [Related]
51. St. Gallen endocrine response classes predict recurrence rates over time.
Koornstra RH; Beelen KJ; Vincent AD; van der Noort V; van Diest PJ; Linn SC
Breast; 2015 Dec; 24(6):705-12. PubMed ID: 26429398
[TBL] [Abstract][Full Text] [Related]
52. Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen.
Winder T; Giamas G; Wilson PM; Zhang W; Yang D; Bohanes P; Ning Y; Gerger A; Stebbing J; Lenz HJ
Pharmacogenomics J; 2014 Feb; 14(1):28-34. PubMed ID: 23459444
[TBL] [Abstract][Full Text] [Related]
53. The CGA gene as new predictor of the response to endocrine therapy in ER alpha-positive postmenopausal breast cancer patients.
Bièche I; Parfait B; Noguès C; Andrieu C; Vidaud D; Spyratos F; Lidereau R; Vidaud M
Oncogene; 2001 Oct; 20(47):6955-9. PubMed ID: 11687975
[TBL] [Abstract][Full Text] [Related]
54. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
55. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer.
McGovern SL; Qi Y; Pusztai L; Symmans WF; Buchholz TA
Breast Cancer Res; 2012 May; 14(3):R72. PubMed ID: 22559056
[TBL] [Abstract][Full Text] [Related]
56. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
57. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment.
Hoppe R; Achinger-Kawecka J; Winter S; Fritz P; Lo WY; Schroth W; Brauch H
Eur J Cancer; 2013 Nov; 49(17):3598-608. PubMed ID: 23968733
[TBL] [Abstract][Full Text] [Related]
58. Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.
Jansen MP; Sas L; Sieuwerts AM; Van Cauwenberghe C; Ramirez-Ardila D; Look M; Ruigrok-Ritstier K; Finetti P; Bertucci F; Timmermans MM; van Deurzen CH; Martens JW; Simon I; Roepman P; Linn SC; van Dam P; Kok M; Lardon F; Vermeulen PB; Foekens JA; Dirix L; Berns EM; Van Laere S
Mol Oncol; 2015 Jun; 9(6):1218-33. PubMed ID: 25771305
[TBL] [Abstract][Full Text] [Related]
59. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
60. Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
Brennan DJ; Laursen H; O'Connor DP; Borgquist S; Uhlen M; Gallagher WM; Pontén F; Millikan RC; Rydén L; Jirström K
Breast Cancer Res; 2011 Jan; 13(1):R12. PubMed ID: 21281480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
